- Bavarian Nordic ( OTCPK:BVNRY ) ( OTCPK:BVNKF ) ( BAVN ) said it signed a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of smallpox/monkeypox vaccine Imvamune worth US$234M in addition to $180M in contract options.
- This was in addition to the US$56M contract awarded in June 2022 to a total value of up to US$470M, the Denmark-based company said in a Sept. 20 press release.
- In addition, Bavarian signed a new multi-year contract with Canada's Department of National Defence (DND) worth US$2M, in addition to US$18M in contract options.
- Bavarian noted that the majority of the order supply will be delivered in 2023 with the option to procure additional doses annually until 2032 for a total additional value of up to US$198M.
For further details see:
Bavarian Nordic to supply more doses of monkeypox vaccine to Canada in contracts worth up to $434M